CoChat

Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study

Cassano, Paolo, Lattanzi, Lorenzo, Fava, Maurizio, Navari, Serena, Battistini, Giulia, Abelli, Marianna, Cassano, Giovanni B · 2005 · The Canadian Journal of Psychiatry

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Objective: The study aimed to assess the antidepressant efficacy and tolerability of adjunctive ropinirole in outpatients with treatment-resistant depression (TRD). Method: The study sample consisted of patients with a major depressive episode (diagnosed according to DSM-IV criteria) and TRD. Ropinirole 0.25 to 1.5 mg daily was added to tricyclic antidepressants or selective serotonin reuptake inhibitors. We conducted assessments at baseline and at weeks 2, 4, 8, 12, and 16. We defined response as a 50% or greater reduction of the Montgomery–Asberg Depression Rating Scale (MADRS) total score plus a score of 1 (“very much improved”) or 2 (“much improved”) on the Clinical Global Impression of Improvement scale at endpoint. Tolerability was monitored with the Dosage Record Treatment Emergent Symptom Scale. Results: Seven patients had major depressive disorder, and 3 had bipolar II disorder. The mean maximum dose of ropinirole was 1.33 mg daily. Mean (SD) scores on the MADRS decreased from 29.6 (7.6) at baseline to 16.9 (12.1) at endpoint ( P < 0.02). At endpoint, 4 of 10 (40%) patients were responders. Two patients discontinued ropinirole because of dizziness. Conclusions: These pilot data suggest that, in selected cases of TRD, ropinirole augmentation of antidepressants is effective and relatively well tolerated.

Overview

Integrity signals

Registry

Crossref · 10.1177/070674370505000612

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 1

  1. Brooks DJ, 1998, Clin Neuropharmacol, 21, 101

Cited by

See all 77

Metadata

Authors
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B.
Affiliations
  • Massachusetts General Hospital (US)
  • University of Pisa (IT)
  • Director, Depression Clinical and Research Program Massachusetts General Hospital, Boston, Massachusetts
Corresponding author
Cassano, Paolo
Venue
The Canadian Journal of Psychiatry
Published
2005-05
Volume
50
Issue
6
Pages
357-360
ISSN
  • 0706-7437 (ISSN-L)
  • 1497-0015
OpenAlex
W2119768046
Cited by
73
References
17
Citations by year
2026: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 3 · 2019: 3 · 2018: 2 · 2017: 4 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 6
FWCI
3.40
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • The Canadian Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ropinirole, treatment-resistant depression, adjunctive therapy, dopamine agonists, antidepressant augmentation, major depressive disorder, bipolar II disorder, tricyclic antidepressants, selective serotonin reuptake inhibitors, tolerability, dizziness
MeSH terms
Adolescent, Adult, Aged, Major Depressive Disorder, Drug Resistance, Female, Humans, Indoles, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Dopamine Agonists, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study. https://app.cochat.ai/papers/10.1177/070674370505000612
The paper
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005). Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674370505000612

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.